Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase NA 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 250Carcinoma, Non-Small-Cell Lung 226Prostatic Neoplasms 118Neoplasms 106Multiple Myeloma 91Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 67Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 48Melanoma 47Carcinoma, Renal Cell 45Leukemia, Lymphocytic, Chronic, B-Cell 44Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Recurrence 41Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Nasopharyngeal Carcinoma 34Lymphoma, Follicular 34Head and Neck Neoplasms 34Pancreatic Neoplasms 32Rectal Neoplasms 31Lymphoma, Large B-Cell, Diffuse 30Endometrial Neoplasms 29

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma, Mucinous × 1 year × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡